NantHealth (NASDAQ: NH) and Simulations Plus (NASDAQ:SLP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.


This table compares NantHealth and Simulations Plus’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NantHealth -225.76% -46.09% -25.23%
Simulations Plus 23.94% 23.95% 18.78%

Institutional & Insider Ownership

7.1% of NantHealth shares are held by institutional investors. Comparatively, 33.6% of Simulations Plus shares are held by institutional investors. 58.0% of NantHealth shares are held by company insiders. Comparatively, 36.9% of Simulations Plus shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.


Simulations Plus pays an annual dividend of $0.24 per share and has a dividend yield of 1.5%. NantHealth does not pay a dividend. Simulations Plus pays out 72.7% of its earnings in the form of a dividend.

Risk and Volatility

NantHealth has a beta of -1.5, indicating that its share price is 250% less volatile than the S&P 500. Comparatively, Simulations Plus has a beta of -0.76, indicating that its share price is 176% less volatile than the S&P 500.

Valuation & Earnings

This table compares NantHealth and Simulations Plus’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NantHealth $100.38 million 3.63 -$184.10 million ($1.78) -1.89
Simulations Plus $24.14 million 11.42 $5.78 million $0.33 48.33

Simulations Plus has lower revenue, but higher earnings than NantHealth. NantHealth is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for NantHealth and Simulations Plus, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NantHealth 0 0 4 0 3.00
Simulations Plus 0 0 0 0 N/A

NantHealth presently has a consensus price target of $9.00, indicating a potential upside of 167.86%. Given NantHealth’s higher possible upside, research analysts plainly believe NantHealth is more favorable than Simulations Plus.


Simulations Plus beats NantHealth on 10 of the 15 factors compared between the two stocks.

NantHealth Company Profile

NantHealth, Inc. is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples. The Company also offers Nant Operating System (NantOS) and NantOS applications to healthcare providers and payors, self-insured employers and biopharmaceutical companies. It offers CLINICS, an integrated solution that includes GPS Cancer, NantOS and the NantOS applications. The CLINICS solution includes System Infrastructure, Knowledge Platform, Provider Platform and Payor Platform.

Simulations Plus Company Profile

Simulations Plus, Inc. (Simulations Plus) develops and produces software for use in pharmaceutical research and for education, and provides consulting and contract research services to the pharmaceutical industry. The Company offers five software products for pharmaceutical research. ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) Predictor is a computer program that takes molecular structures as inputs and predicts over 140 different properties for them at the rate of about 200,000 compounds per hour. MedChem Designer includes a small set of ADMET Predictor property predictions, allowing the chemist to modify molecular structures. MedChem Studio is a tool for medicinal and computational chemists for both data mining and for designing new drug-like molecules. DDDPlus simulates in-vitro laboratory experiments used to measure the rate of dissolution of the drug. GastroPlus simulates the absorption, pharmacokinetics, and pharmacodynamics of drugs.

Receive News & Stock Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related stocks with our FREE daily email newsletter.